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ABSTRACT
The 4th annual Ontario Thoracic Cancer Conference at 
Niagara-on-the-lake focused on the themes of innova-
tions in the management of lung cancer, controversies 
in the management of esophageal cancer, and molecu-
lar targeted therapies in lung cancer. This conference 
summary highlights the presentations and provides 
clinicians with a referenced update on these topics.
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1.  INTRODUCTION
The 4th annual Ontario Thoracic Cancer Conference 
was held at Niagara-on-the-lake, april 17–19, 2009, 
bringing together health care professionals interested 
in thoracic oncology in the province of Ontario. 
attendees at this conference spanned the disciplines 
of surgical, radiation, and medical oncology, respi-
rology, pathology, nursing, support services, and 
radiation therapy. advocates for lung cancer patients 
were also in attendance. For the first time this year, a 
session on the management of esophageal cancer was 
presented, as were a session on new innovations in 
radiation therapy and an update on molecular targeted 
therapy. a poster session highlighted research work 
being done by trainees, whose abstracts are published 
in the appendix to this report.
2.  HIGHLIGHTS
This year’s meeting highlighted three themes:
Innovations in the management of lung cancer • 
Controversies in the management of esopha- • 
geal cancer
Molecular targeted therapies for lung cancer • 
2.1  Innovations in Lung Cancer Management
2.1.1  Radiation Therapy
Professor Jake Van dyk, from the University of 
Western Ontario and the london Health Sciences 
Centre, delivered the first keynote address, “New 
advances in radiation Therapy for Non-Small Cell 
Lung Cancer” (n s c l c ).
Three major problems are encountered in the 
treatment of n s c l c :
accurate delineation of the target • 
Precision delivery of high-dose radiation to the target • 
Minimization of radiation exposure to surround- • 
ing normal critical tissues—for example, normal 
lung and esophagus
The potential solutions for these problems involve 
better imaging by incorporating positron-emission 
tomography (p e t) for accurate localization and by 
avoiding geometric misses 1–3, by using image-guided 
radiation therapy 4 for dose escalation and tumour 
adaptive changes to improve local control 5,6, and by 
minimizing collateral damage to critical tissues.
Innovative new radiation delivery treatment sys-
tems that include the use of tomotherapy 7, robotic 
radiosurgery, stereotactic body radiation treatment, 
and magnetic resonance–guided radiation have been 
evaluated. The use of respiratory gating methods to 
minimize exposure of normal lung tissue is important 
in the development of these new, highly conformal 
radiation techniques, so as to reduce the risk of radia-
tion pneumonitis as the radiation dose is escalated 
beyond traditional levels.
dr. Stewart Gaede, from the london Health 
Sciences Centre, spoke on “respiratory Gating in 
lung Cancer applications, Including 4d CT–Based 
Treatment Planning.” respiratory management 
techniques that include tumour tracking methods, 
tumour immobilization, breath-hold methods, and 
respiratory gating were reviewed. at the london 112
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regional Cancer Centre, 96 patients have been treated 
using respiratory-gated radiotherapy with either liver 
metastases or lung tumours. Based on evaluation 
of dose–volume histogram parameters, respiratory 
gating reduces the amounts of normal lung and liver 
that receive a significant dose. However, optimal 
techniques are still being investigated to correlate the 
use of external marker motion with internal tumour 
or organ motion 8. despite the uncertainties of dose 
distribution and organ tracking, the use of respiratory 
gating is a promising strategy to aid in dose escalation, 
in the avoidance of critical structures influenced by 
respiration, and in the delivery of intensity-modulated 
radiation treatments.
2.1.2  Reducing Wait Times
dr. Carol Sawka, Vice President, Clinical Programs 
and Quality Initiatives, Cancer Care Ontario (c c o ), 
gave the second keynote address on “access to Can-
cer Services in Ontario: a Progress report.”
Access to care can be defined as “equitable and 
timely access to appropriate care when needed.” The 
patient journey from onset of symptoms to treatment 
is influenced by many factors, which include the 
type and stage of cancer, the treatment and services 
selected by the physician, and patient choices for 
therapy. Cancer Care Ontario is dedicated to improv-
ing the patient experience, and the organization uses 
a number of strategies to improve the performance 
of cancer services. It has created the Cancer System 
Quality Index (c s q i ) 9, a Web-based public reporting 
tool that serves as a system-wide monitor tracking 
the quality and consistency of key cancer services 
that span the spectrum from prevention to end-of-life 
care. The c s q i  has about 30 key indicators, and each 
indicator is a specific measure of progress against 
one of six goals that help focus efforts to improve 
the cancer system in Ontario. One of the key indica-
tors is wait times, whose principle is that wait time 
targets should be based on the biologic behaviour 
of the cancer. Wait times for surgical and radia-
tion therapy are improving, but access to systemic 
therapy still needs improvement. The lung Cancer 
disease Pathway Management initiative at c c o  will 
focus on the patient journey to make improvements 
in the cancer system. It will bring together experts 
focused on lung cancer to evaluate the continuum 
of care, to map the patient journey, to evaluate the 
system’s performance, and to develop an integrated 
improvement program.
Methods to improve the performance of the 
system have included the development of thoracic 
diagnostic assessments units (d a u s) as presented by 
dr. Matthew Kilmurry and Ms. Jennifer Parkins from 
the Grand river regional Cancer Centre.
The d a u  was a joint venture between the re-
gional cancer centre and its two host hospitals in 
the Waterloo–Wellington local Health Integration 
Network (l h i n ). The l h i n ’s lung cancer patients 
have a long wait time and uncoordinated care path-
ways for referrals and diagnostic imaging. The d a u  
provides timely access to diagnosis and treatment, 
interdisciplinary focused care, multidisciplinary case 
conferencing, and implementation of evidence-based 
care. The most common diagnostic test ordered is a 
computed tomography (c t )–guided biopsy, followed 
by bronchoscopy, mediastinoscopy, and p e t imaging. 
To reduce the wait time from c t  to diagnosis, pre-
booked slots were made available in medical imaging. 
as a result, wait time was reduced to 27 days from 
74 days, which parallels the initial experience of the 
Time to Treat initiative at the Toronto East General 
Hospital 10. Future plans include integrating the d a u  
into the surgical oncology program, expanding the 
nursing role, and further engaging regional physi-
cians. Cancer Care Ontario has set up a guideline on 
the establishment of diagnostic programs 11.
a diagnostic test commonly requested through 
the d a u  is p e t imaging. an update on the role of p e t 
in staging and managing lung cancer was presented 
by dr. Yee Ung, from the Odette Cancer Centre. In 
lung cancer, p e t imaging shows high sensitivity and 
specificity over conventional imaging, a finding that 
has been systematically reviewed12. More recently, 
two clinical trials in lung cancer by the Ontario 
Clinical Oncology Group have shown the utility of 
p e t for staging the mediastinum in early-stage re-
sectable lung cancer 13 and in selecting appropriate 
locally advanced lung cancer patients for aggressive 
combined-modality therapy 14. as a result of these 
clinical trials, lung cancer patients in Ontario now 
have access to p e t imaging as part of their care when 
they fit the foregoing criteria.
2.1.3  Interdisciplinary Care
The patient journey for lung cancer involves interac-
tion with many disciplines, and there is an expanding 
role for the advanced practice nurse (a p n ), as pre-
sented by Ms. lorraine Martelli–reid, an a p n  from 
the Juravinski Cancer Centre.
The roles of the a p n  span the spectrum from 
clinical care to education, research, and organizational 
leadership. a retrospective review at the Juravinski 
Cancer Centre (j c c ) of patients undergoing postop-
erative adjuvant chemotherapy with cisplatin and 
vinorelbine in the National Cancer Institute of Canada 
(n c i c ) Clinical Trials Group (c t g ) b r .10 15 trial showed 
an absolute survival difference of 15%. However, the 
chemotherapy regimen is difficult to complete: only 
50% of patients on the n c i c  b r .10 clinical trial were 
able to complete all 4 cycles of chemotherapy. at the 
j c c , however, 84% of patients were able to complete 
the 4 cycles. Support from an a p n  is vital in helping 
to manage symptoms during chemotherapy and in 
providing education and counselling for the patients. 
a novel a p n -led “Take a Breather Clinic” was estab-
lished to help lung cancer patients with symptoms of 
dyspnea. Dyspnea had been identified as a significant 113
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symptom using the Edmonton Symptom assessment 
System (e s a s ).
Use of the e s a s  as a common tool for assessment 
was initiated through the Provincial Palliative Care 
Integration Project (p p c i p) funded by the Ministry of 
Health and long-Term Care and c c o . dr. Jeff Myers, 
palliative physician and Toronto Central l h i n  lead for 
the project, indicated that the aim was to target all 
lung cancer and palliative care patients in the regional 
cancer centres and all palliative patients in the home 
setting. By using common tools that incorporate a 
symptom measurement scale (that is, the e s a s  16), 
symptom management guidelines for intervention, and 
a palliative performance scale, it would be possible 
to evaluate patient symptoms and to monitor progress 
through the course of a patient’s care. The success 
of the p p c i p led to the next stage (that is, the Ontario 
Cancer Symptom Management Collaborative), which 
includes all cancer patients with participation of all 
regional cancer centres and community care access 
centres. This project has given a “voice” to the pa-
tient’s symptoms, which may or may not be usually 
discussed, and has provided a common language for 
communication between care providers.
2.2  Controversies in the Management of Esophageal 
Cancer
This year’s meeting explored selected issues in 
esophageal cancer. adenocarcinomas of the esopha-
gus and gastroesophageal junction are increasing in 
incidence, and squamous cell cancers are decreas-
ing. The 5-year survival rates are poor in surgically 
resected patients, emphasizing the need for more 
effective adjunctive therapies. dr. Jennifer Knox 
from the Princess Margaret Hospital reviewed the 
major clinical trials involving preoperative chemo-
therapy 17–19 or preoperative chemoradiation 20.
Preoperative chemoradiation for adenocarcino-
mas improves overall survival and achieves higher 
pathologic complete response rates than are seen with 
chemotherapy alone, but the regimen is more toxic. 
Improvement in overall survival is less certain with 
preoperative chemoradiation in squamous cell carci-
nomas, but local control is improved over that with 
surgery alone. The ability to evaluate response to neo-
adjuvant therapy would be useful for prognostication. 
The m u n i c o n  trial 21 evaluated the strategy of using p e t 
to determine the length of preoperative chemotherapy 
before surgery in locally advanced gastroesophageal 
junction cancers. In that trial, patients underwent a p e t 
scan at baseline and then proceeded to neoadjuvant 
chemotherapy with cisplatin and 5-fluorouracil. After 
2 weeks of therapy, a re-evaluation p e t scan separated 
the metabolic non-responders (less than 35% decrease 
in standardized uptake value) from the responders. 
The non-responders by p e t proceeded to surgery im-
mediately; the responders continued the rest of their 
chemotherapy to 12 weeks before receiving surgery. 
responders by p e t had a 96% r0 resection rate and a 
58% major pathologic response (defined as less than 
10% residual tumour).
The use of p e t in radiation treatment planning was 
evaluated by dr. danny Vesprini and colleagues from 
the Odette Cancer Centre. Their study evaluated the 
effect of the addition of fused p e t–c t  imaging over 
c t  alone in the identification of the gross tumour 
volume (g t v ) in patients with esophageal cancer 22. 
Ten patients with esophageal cancer underwent p e t 
and c t  imaging in radiation treatment position, and 
the resulting image sets were fused. Six radiation 
oncologists independently contoured the g t v  using 
c t  data alone, supplemented with standardized clini-
cal and diagnostic imaging information. The same 
radiation oncologists then contoured the g t v  using the 
co-registered p e t–c t  images. The standard deviation 
of the g t v  length and volume were used a measure 
of inter-observer and intra-observer variation. The 
average observer agreement index using p e t–c t  was 
72.7% as compared with 69.1% using c t  alone. The 
p e t–c t significantly improved both inter-observer 
and intra-observer variability in the identification of 
the primary g t v .
2.3  Molecular Targeted Therapies for Lung Cancer
The third keynote address on “Current Perspectives 
in the Treatment of advanced Non-Small Cell lung 
Cancer” was given by dr. Natasha leighl, from the 
Princess Margaret Hospital.
as the biology of tumour progression becomes 
better understood, newer targets for biologic thera-
pies will become available for clinical trials. Cur-
rently, a wealth of molecular targeted therapies are 
under investigation in n s c l c . The most promising 
new therapies target either the vascular endothelial 
growth factor (v e g f ) 23 or the epidermal growth fac-
tor receptor (e g f r ) 24. Two important randomized 
phase iii clinical trials evaluated the addition of be-
vacizumab to standard chemotherapy as compared 
with standard chemotherapy alone in advanced-stage 
(iiib/iv) and recurrent n s c l c . The Eastern Cooperative 
Oncology Group E4599 trial 25 and the a v a il trial 26 
showed improved progression-free survival for their 
bevacizumab arms. In the E4599 trial, overall median 
survival also improved to 12.3 months from 10.3 
months [hazard ratio (h r ): 0.79; p = 0.003], and the 
adenocarcinoma subgroup had a more significant im-
provement in overall median survival to 14.2 months 
(h r : 0.69). The a v a il trial did not demonstrate a sur-
vival benefit. The incidence of grade 3 or more serious 
adverse events on these trials was low, ranging from 
0.3% to 9% for bleeding, hypertension, proteinuria, 
febrile neutropenia, and arterial thrombosis.
a promising v e g f  small-molecule inhibitor, 
cediranib, was evaluated by the n c i c  c t g  in a phase ii/
iii study design—the n c i c  b r .24 trial. Patients were 
randomized to carboplatin and paclitaxel with 114
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cediranib or a placebo; the cediranib arm had an in-
creased response rate of 38% as compared with 16% 
(h r : 0.77) 27, but some toxic deaths from dehydration 
and diarrhea occurred. The follow-up trial, n c i c  b r .29 
will use a lower dose of cediranib to reduce the oc-
currence of side effects.
The f l e x trial evaluated the use of cisplatin and 
vinorelbine with or without cetuximab (a monoclonal 
antibody against e g f r ) in first-line treatment of stage 
iiib/iv n s c l c . The cetuximab arm had a median over-
all survival of 11.3 months as compared with 10.1 
months, and a 1-year survival of 47% as compared 
with 42% (h r : 0.871; p = 0.044) 28. Patients who de-
veloped an early acne-like rash experienced a median 
overall survival of 15 months.
a current controversy is the role for maintenance 
therapy after completion of first-line treatment with 
a platinum doublet. In a trial by Ciuleanu et al. 29 of 
maintenance after completion of platinum chemother-
apy, patients were randomized to either pemetrexed 
or placebo (2:1 randomization), resulting in a median 
progression-free survival of 4.3 months as compared 
with 2.6 months (h r : 0.502; p < 0.00001), and an 
improvement in overall survival to 13.4 months as 
compared with 10.6 months (h r : 0.79; p = 0.012), with 
a significant difference of 14.4 months as compared 
with 9.4 months (p = 0.0025) in non-squamous histol-
ogy. Similar results were seen for the use of targeted 
therapies for maintenance on the s a t u r n  30 and at l a s  31 
trials that used erlotinib, or bevacizumab with or with-
out erlotinib, although survival data are pending.
3.  THE GREAT DEBATES
Three issues were debated at this year’s meeting:
Stereotactic body radiation therapy ( •  s b r t ) com-
pared with surgery for T1N0 lung cancer
Preoperative compared with postoperative  • 
chemoradiation for esophageal cancer
Endoscopic mucosal resection compared with  • 
surgery for esophageal cancer
3.1  SBRT Versus Surgery for T1N0 NSCLC
dr. Patrick Cheung, Odette Cancer Centre, debated 
dr. richard Inculet, london Health Sciences Centre 
in the first debate of radiation versus surgery for 
early-stage n s c l c .
a comparison of current outcomes in patients 
treated using s b r t  with those in patients undergoing 
surgery for stage i n s c l c  are limited by the accuracy 
of staging. Patients referred for radiation often have 
significant medical comorbidities that preclude sur-
gical resection, and they are often clinically staged 
where surgical candidates are pathologically staged. 
In addition, the radiation dose used to control early-
stage n s c l c  is very important: The dose given must be 
effective enough to eradicate small lung cancers.
In a large retrospective multi-institutional study 
of s b r t  using biologically effective doses of radiation 
for stage i n s c l c , a 5-year survival rate of 53.9% was 
achieved, and in the subset of operable lung patients, 
the survival increased to 70.8% 32. The toxicities 
associated with s b r t  for peripheral locations are 
minimal; they include radiation pneumonitis (5.4%), 
mild dermatitis (1.2%), and rib fracture (1.6%). 
Centrally located lesions may carry a higher risk of 
bronchial stenosis with lung collapse, and current 
clinical trials are evaluating the safety of treating 
central lesions with s b r t . The major concern with 
s b r t  is the effect of radiation on patients with poor 
pulmonary function. However, an analysis of 70 
medically inoperable stage i n s c l c  patients with 
poor baseline pulmonary function did not predict for 
decreased survival or decreased pulmonary function 
after treatment 33.
Surgical resection is still the standard of care for 
resectable early-stage n s c l c . Innovations with mini-
mally invasive surgical techniques—that is, video-
assisted thoracoscopic surgery (v a t s )—have reduced 
surgical morbidity. In selected cases, outcomes may 
be better than those with standard lobectomy 34. The 
safety and efficacy of v a t s  lobectomy compared 
with open lobectomy have been systematically re-
viewed, and no statistically significant differences 
were observed in terms of postoperative prolonged 
air leak, arrhythmia, pneumonia, mortality, or risk of 
locoregional recurrence 35. Today, patients that might 
not have been considered for open lobectomy may 
therefore, with v a t s , still be surgical candidates.
The choice of s b r t  or surgery for stage i n s c l c  will 
be multifactorial, but appropriately selected patients 
will do well with either option.
3.2  Preoperative Versus Postoperative Chemoradia-
tion for Esophageal Cancer
dr. rebecca Wong, Princess Margaret Hospital, de-
bated dr. richard Malthaner, london Health Sciences 
Centre, in the second debate on esophageal cancer.
Surgery alone is insufficient treatment for resect-
able, but locally advanced, cancers of the esophagus 
because locoregional and distant recurrence rates 
are significant. Therefore using either preoperative 
or postoperative therapy may be useful in improving 
outcomes. The advantage of using a preoperative 
approach are these:
Tumour downstaging can occur before surgi- • 
cal resection.
radiation target volumes are smaller. • 
Perioperative morbidity is less. • 
radiation dose is more effective in an undis- • 
turbed tumour.
In esophageal cancer, 10 randomized controlled 
clinical trials have involved 1209 patients. The  h r  
for all-cause mortality was 0.81 for neoadjuvant 115
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chemoradiotherapy as compared with surgery alone, 
corresponding to a 13% absolute difference in survival 
at 2 years favouring neoadjuvant chemoradiation 20.
Postoperative chemoradiotherapy holds these 
advantages:
Postoperative adjuvant therapy can be tailored  • 
using the accurate stage.
Unnecessary treatment of early-stage esophageal  • 
cancer is avoided.
Surgery is better tolerated. • 
Immediate improvement is achieved in the major  • 
presenting symptom, dysphagia.
No randomized controlled trials have compared 
postoperative chemoradiation with surgery alone, 
and none have compared preoperative chemora-
diation with postoperative chemoradiation. at the 
london regional Cancer Centre, a retrospective 
review of patients with lymph-node-positive disease 
who, after surgical resection, were given postopera-
tive chemoradiation showed that the postoperative 
treatment, as compared with no treatment, was 
associated with significantly longer survival 36. a 
definitive clinical trial comparing preoperative with 
postoperative chemoradiation would be useful in 
determining the precise benefit in terms of survival 
and quality of life.
3.3  Endoscopic Mucosal Resection Versus Surgery 
for Esophageal Cancer
dr. Norman Marcon, St. Michael’s Hospital, debated 
dr. richard Inculet, london Health Sciences Centre, 
in the third debate on the treatment of early esopha-
geal cancer.
The dilemmas faced in the treatment of high-
grade dysplasia and intramucosal adenocarci-
noma 37 include
the confidence of the pathologic diagnosis, • 
the malignant risk of the lesion, • 
the completeness of the resection, • 
the morbidity and mortality of the treatment, and • 
the eradication of the disease. • 
Endoscopic therapy can be either endoscopic mu-
cosal resection or endoscopic submucosal dissection 
(basically removing the mucosal tissue down to and 
including the submucosa). For endoscopic resection 
to be successful, there must be accurate staging of 
the disease, a low failure rate, an accurate method of 
surveillance, good functional results post treatment, 
and an effective way to deal with the underlying 
cause—that is, gastroesophageal reflux disease 38. For 
surgical resection to be successful, there must be a low 
complication rate, a reasonable functional result, and 
a high curative potential 39. Both treatment options 
are suitable, depending on patient compliance, disease 
characteristics, extent of disease, and expertise of the 
treating physician.
4.  POSTER PRESENTATIONS
research by the medical trainees was highlighted 
in the poster presentations. The abstract review 
committee selected two posters for oral presenta-
tion. The first, by Dr. Meredith Giuliani, was titled 
“Prophylactic Cranial Irradiation Utilization rates in 
limited-Stage Small-Cell lung Cancer.” The second, 
by dr. Jeffrey Cao, was a “Systematic review of 
the Cost-Effectiveness of PET in Staging of Non-
Small-Cell lung Cancer and Management of Solitary 
Pulmonary Nodules.” The abstracts are published in 
the appendix to this report.
5.  SUMMARY
The Ontario Thoracic Cancer Conference continues 
to bring together people interested in the management 
of patients with thoracic malignancies. It remains an 
excellent forum to foster research and wide multi-
disciplinary interaction. We extend our thanks to all 
who made this meeting such a success, including our 
sponsors, Astra Zeneca and Lilly (platinum level), 
Olympus (gold level), and Boehringer Ingelheim 
(silver level).
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APPENDIx
abstracts Presented at the 4th Ontario Thoracic Cancer Conference
10 Years of VCRT: An Analysis of a Novel Protocol of Combined 
Concurrent Chemoradiation in Unresectable Non-Small-Cell  
Lung Cancer
Waters E, Rodrigues G, Vincent M, Dingle B. London Regional Cancer 
Centre, University of Western Ontario,  
London, Ontario.
Background and Objectives:  The london regional Cancer Program 
(l r c p ) employs a unique schedule of concurrent chemoradiation, termed v c r t  
(vinblastine, cisplatin, radiation therapy), for the treatment of unresectable 
stage iiia and iiib non-small-cell lung cancer (n s c l c ). The protocol consists of 
100 mg/m2 cisplatin and 6 mg/m2 vinblastine (reduced to 4.2 mg/m2 during 
cycles 3 and 4), split over days 1–3, given once every 3 weeks for 4 cycles, with 
60 Gy of concurrent radiation over 6 weeks during cycles 3 and 4.
The objective of the present study was to determine overall survival and 
to characterize outcomes of patients treated with v c r t .
Methods:  This retrospective analysis, with a focus on overall survival 
and toxicities, reports a cohort of 294 patients who underwent v c r t  at the l r c p  
between 1996 and 2006.
Results:  The overall 5-year survival, determined using Kaplan–Meier 
methodology, was 19.8%, and the median survival duration was 18.2 months. 
Reported grades 3 and 4 toxicities included neutropenia (39%), anemia 
(10%), pneumonitis (1%), and esophagitis (3%). Log-rank tests demonstrated 
significant differences in survival between groups of patients for completion 
surgery, use of radiation therapy, and cisplatin dose. Similarly, univariate Cox 
regression showed that completion surgery, use of radiation therapy, cisplatin 
dose, and vinblastine dose were significant factors in the survival of all stage iii 
n s c l c  patients treated with v c r t .
Discussion and Conclusions:  This retrospective analysis reveals an 
overall survival comparable to that of other current combined chemoradiation 
protocols. The success of the v c r t  protocol seems to be dose-dependent.
Characteristics of Lung Cancer at a Regional Cancer Centre
Alam Y, Zhao Y. Windsor Regional Cancer Centre, Windsor, Ontario; 
Schulich School of Medicine, University of Western Ontario,  
London, Ontario.
Background and Objectives:  lung cancer is strongly correlated with 
cigarette smoking, although other environmental and genetic components may 
also play a role. There have been public concerns in Southwestern Ontario 
that environmental and occupational exposures are resulting in a higher lung 
cancer rate.
The present study aimed to further characterize the smoking habits, histol-
ogy subtypes, stage at diagnosis, and 5-year survival rates in newly diagnosed 
lung cancer patients in the Southwestern Ontario region in 2003.
Methods:  We retrospectively reviewed all incident lung cancer patients 
seen at the Windsor Regional Cancer Centre (w r c c ) in 2003. Data were collected 
from the e-chart database used at the centre. age, presenting symptoms, histology, 
initial clinical staging, and 5-year survival were recorded.
Results:  In 2003, 189 new lung cancer cases were seen at the w r c c . In 
93.65% of the cases, the patient was 50 years of age or older. In 93.12% of the 
cases, the patient was a smoker or ex-smoker. Weight loss, cough, and dyspnea 
were the most common presenting symptoms. Non-small-cell lung cancer 
(n s c l c ) constituted 74.07% of the cases, of which 64% were stage iii or iv at 
initial diagnosis. The small-cell subtype accounted for 14.99% of the cases, 
and 61.76% of those patients had extensive disease at diagnosis. Survival at 
5 years was 5.82%.
Discussion and Conclusions:  More than 90% of newly diagnosed lung 
cancer patients from the Southwestern Ontario region in 2003 were smokers and 
50 years of age or older. The histology subtypes and survival trends for these pa-
tients were similar to trends published elsewhere in the literature. another review 
for 2008, to see if the characteristics have changed, would be interesting.118
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Adjuvant Chemotherapy in Non-Small-Cell Lung Cancer—Boon 
or Bane?
Kuruvilla MS, Martelli–Reid L, Goffin JR, Arnold A, Ellis PM. Jurav-
inski Cancer Centre, McMaster University, Hamilton, Ontario.
Background and Objectives:  Published data support the use of cisplatin–
vinorelbine doublet as adjuvant chemotherapy in completely resected non-small-
cell lung cancer (n s c l c ). However, data also demonstrate a need for frequent 
dose reductions. Consequently, many centres across Canada have been reluctant 
to adopt this practice.
The primary objective of the present study was to assess the deliverability of this 
adjuvant regimen in patients with stage ib, ii, and iii n s c l c  within our center. Secondary 
objectives were to determine the tolerability and toxicity of this regimen.
Methods:  We retrospectively reviewed patients with n s c l c  receiving 
adjuvant cisplatin–vinorelbine at the Juravinski Cancer Centre between January 
2005 and September 2007. demographics, total chemotherapy dose, treatment 
duration, and toxicity profiles were abstracted. Relative dose intensity (r d i ) was 
calculated as a marker of deliverability.
Results: adjuvant cisplatin–vinorelbine was administered to 41 patients. 
The median weekly dose intensity was 23.5 mg/m2 (range: 13.1–27.9 mg/m2) 
for cisplatin and 18.8 mg/m2 (range: 8.4–25.1  mg/m2) for vinorelbine. The 
median r d i s for cisplatin and vinorelbine were 94% and 63%. Of the treated 
patients, 71% underwent all 4 cycles; 61% received all treatments of cisplatin, 
and 16%, all treatments of vinorelbine. Toxicities at grade 3 or higher included 
anemia (12%), neutropenia (63%), febrile neutropenia (7%), constipation (2%), 
and fatigue (18%). Blood transfusions were given to 24% of the patients, and 
18% received erythropoiesis-stimulating agents. less severe toxicities included 
peripheral neuropathy, ototoxicity, mucositis, vomiting, alopecia, and flare of 
surgical site pain.
Discussion and Conclusions: The deliverability of adjuvant cisplatin–
vinorelbine, administered weekly for 16 weeks, was as good as or better than 
that in the a n i t a  trial. This finding helps to attenuate concerns about the toler-
ability of the regimen.
Differences in V20 and Contoured Radiotherapy Treatment Vol-
umes in Stage III Non-Small-Cell Lung Cancer with the Addition 
of Positron-Emission Tomography Imaging to Standard Computed 
Tomography Imaging
Chan E, Kiss A, Balogh J, Barbera L, Cheung P, Poon I, Spayne J, 
Ung YC. Odette Cancer Centre, Sunnybrook Health Sciences Centre, 
University of Toronto, Toronto, Ontario.
Background:  Imaging by positron-emission tomography (p e t) is increas-
ingly used to stage and plan radiotherapy (r t ) in patients with non-small-cell 
lung cancer (n s c l c ). The effect of this approach on r t  volumes is not yet fully 
known. The present study evaluated differences in V20 (a predictor for radiation 
pneumonitis) and contoured r t  volumes in p e t- versus computed tomography 
(c t )–based plans for stage iii n s c l c .
Methods: as part of their work-up, 18 patients underwent p e t and c t . The 
r t  volumes were initially contoured using the c t  data alone. Contours were then 
modified by information from the p e t imaging. differences between the paired 
contours and V20 determinations for each patient were calculated.
Results:  The average difference between the total contoured gross tumour 
volume for the p e t and c t  approaches was similar (1.13 cm3). In 5 of 18 patients, 
volume differences of more than 25 cm3 were observed. The average difference 
between the contoured planning target volumes for the two approaches was more 
varied (p e t volumes were larger on average by 12.99 cm3). In 6 of 15 patients, 
volume differences of more than 50 cm3 were observed. The calculated V20 was 
similar between the two approaches (c t  plans were larger on average by 0.19%) 
with a range of –2.8% to 4.5%. The range of V20 based on c t was 15.2% to 37.7%; 
on p e t, it was 14.7% to 36.7%.
Conclusions:  Overall, there appears to be only a small change between 
the contoured g t v  and the planning target volume when using p e t or c t  imag-
ing. However, in a proportion of patients, the contoured volumes are quite 
different. The ultimate effect of these differences will need to be validated by 
clinical outcomes.
Inter-observer and Intra-observer Reliability for Lung Cancer 
Target Volume Delineation
Louie A, Rodrigues G, Gaede S. London Regional Cancer Centre, 
University of Western Ontario, London, Ontario.
Objectives:  The purpose of the present study was to investigate in-
ter- and intra-observer target volume delineation (t v d ) error in the setting of 
four-dimensional (4D) computed tomography (c t) image data acquisition in 
thoracic tumours.
Methods:  Six radiation oncologists contoured the primary and nodal gross 
tumour volume (g t v ) of 10 lung tumours on the 10 respiratory phases of a 4D c t  
scan. The coefficient of variation (c o v ) and the percentage shared internal target 
volume (si t v) of the 6 physicians for each patient was used to assess inter- and 
intra-observer variability.
analysis of variance was performed to assess differences in inter- and 
intra-physician variability based on patient case difficulty, respiratory phase, 
physician seniority, and physician observer.
Results:  Inter-physician percentage si t v for primary tumour ranged 
from 31.1% to 83.3% [standard deviation (s d): 4.4%–15.8%] and from 16.4% 
to 66.8% (s d: 5.8%–21.1%) for nodes. Intra-physician si t v for primary tumour 
ranged from 59.6% to 72.7% (s d: 13.0%–23.9%), and from 28.3% to 57.0% (s d: 
18.6%–34.2%) for nodes. Analysis of variance for c o v s found case difficulty 
(easy vs. difficult) to be significant for inter-physician primary tumour and intra-
physician nodal disease delineation. Physician seniority, respiratory phase, and 
individual physician were not found to be significant for t v d  error.
Conclusions:  High observer variability in t v d  continues to be a major 
source of error in the 4d c t era for lung cancer. Inter-physician variability appears 
to be the more significant source of this error than intra-physician variability. 
development of measures to reduce inter- and intra-observer t v d  variability are 
necessary to the delivery of high-quality radiotherapy.
Stereotactic Body Radiotherapy for Inoperable Patients with Early 
Stage Non-Small-Cell Lung Cancer
Taremi M, Dahele M, Bezjak A. Princess Margaret Hospital, Univer-
sity Health Network, University of Toronto, Toronto, Ontario.
Background and Objectives:  Stereotactic body radiotherapy (s b r t ), a 
technique to deliver high-dose radiation in each fraction, is expected to provide 
high rates of local control.
Methods:  Patients eligible for our lung s b r t  research Ethics Board–
approved protocol included those with inoperable early-stage n s c l c  (T1/T2, N0, 
M0), and patients with a limited number of pulmonary metastases.
Two dose/fractionation (fr) schedules for peripheral tumours are 48 Gy/4 fr 
for T1 and 54–60 Gy/3 fr for T2 tumours. If the tumour is in proximity to midline 
structures, 60 Gy/8 fr or 50 Gy/10 fr is used. Toxicity and tumour response are 
assessed using Common Terminology Criteria for adverse Events v.3 and the 
response Evaluation Criteria in Solid Tumors criteria respectively.
Results:  Between December 2004 and July 2008, 111 patients (median 
age: 72 years) were treated. The data for 96 patients with early-stage non-small-
cell lung cancer (100 lesions) and a median follow-up of 16.4 months were 
analyzed for this report. In patients with at least 6 months of follow-up, we 
observed 42 partial responses, 35 complete responses, 10 stable disease, and 
11 disease progression. local failure occurred for 9 lesions, 5 of which were 
treated with 50 Gy/10 fr.
The estimated 3-year overall survival was 48% [95% confidence interval 
(c i ): 32% to 62%]; cause-specific survival was 83% (95% c i : 72% to 94%). The 
most common acute toxicity was fatigue (42 patients). No patient had grade 4 
or 5 toxicity.
Discussion and Conclusions:  In early-stage n s c l c , s b r t  is an effective 
and well-tolerated treatment. However, careful patient selection, attention to 
planning and treatment delivery, and ongoing follow-up is needed to fully define 
the therapeutic ratio for this technique.119
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Prophylactic Cranial Irradiation Utilization Rates in Limited-
Stage Small-Cell Lung Cancer
Giuliani M, Hope A, Sun A, Ma C, Brade A, Cho JBC, Bezjak A. 
Princess Margaret Hospital, University Health Network, University of 
Toronto, Toronto, Ontario.
Background and Objectives:  Prophylactic cranial irradiation (p c i) 
improves survival in patients with limited-stage small-cell lung cancer (l s-
s c l c ). The objective of the present audit was to assess the adoption of p c i  at 
our institution.
Methods:  From 1997 to 2007, 796 patients were treated at Princess Mar-
garet Hospital for s c l c . Of these 796 patients, the 226 (28.4%) who received 
radical l s-s c l c  treatment formed the basis of this project. Brain failure-free 
survival (f f s) was estimated by the Kaplan–Meier method, comparing patients 
treated with and without p c i .
The p c i  uptake was determined, and for patients not receiving p c i , the reason 
was recorded if it was available. The Fisher exact test was used to compare rates 
of p c i  use during 1997–2001 and 2002–2007.
Results:  Median follow-up was 15.5 months (range: 2–130 months). From 
1997 to 2007, 55.3% (n = 125) of radically treated l s-s c l c  patients received p c i . 
Brain f f s at 6, 12, and 24 months was 94.3%, 69.3%, and 32.0% respectively 
for patients who did not receive p c i  and 100.0%, 94.6%, and 76.8% respectively 
for patients who did receive that treatment (p < 0.0001). A nonsignificant in-
crease in p c i  uptake, 51.7% to 59.1% (p = 0.29), occurred from 1997–2001 to 
2002–2007. The most common reasons for not receiving p c i  were patient refusal 
and disease progression.
Discussion and Conclusions:  Prophylactic cranial irradiation significantly 
improves brain f f s; only half of l s-s c l c  patients at our institution received p c i . 
Uptake of p c i  has not significantly increased in recent years. A thorough explora-
tion of patient concerns regarding p c i  may increase the uptake rate.
Systematic Review of the Cost-Effectiveness of Positron-Emission 
Tomography in the Staging of Non-Small-Cell Lung Cancer and 
the Management of Solitary Pulmonary Nodules
Cao JQ, Rodrigues GB. London Health Sciences Centre, University of 
Western Ontario, London, Ontario.
Background and Objective:  This systematic review describes the cost-
effectiveness of positron-emission tomography (p e t) imaging in the staging of 
n s c l c  and the management of solitary pulmonary nodules (s p ns).
Methods:  We conducted systematic literature searches in the m e d l i n e /
Prem e d l i n e , e m b a s e , and U.K. National Health Service databases. Measurement 
of study quality was assessed by the validated Quality of Health Economic 
Studies (q h e s ) instrument. Studies with a q h e s  score below 75 were excluded. 
Characteristics including study methodology, assumptions, and cost effective-
ness metrics [incremental cost-effectiveness ratio—i c e r —based on life-years 
saved and average cost savings per patient (a c s p )] were abstracted. Descriptive 
statistics were generated with cost amounts converted to a common inflation-
adjusted 2007 U.S. dollar.
Results:  The 20 studies that met all inclusion criteria, including acceptable 
q h e s  scores as determined by two reviewers (mean: 87.8), were based on the 
national health insurance payer perspective of 8 different countries. Investiga-
tions assessed the s p n scenario (n = 8), the staging scenario (n = 11), and the s p n 
and staging scenarios (n = 1) together. Mean assumed cost of p e t scanning was 
$1267 (range: $769–$2580) in these studies. Median i c e r s for s p n and staging 
were $2039 (range: $181–$3927) and $4037 (range: $527–$32618) respectively. 
Median a c s p s for s p n and staging were $518 (range: $66–$1480) and $1390 
(range: $143–1633) respectively.
Conclusions:  reported cost-effectiveness metrics are highly variable and 
depend on input variables and assumptions including: cost, disease prevalence, 
diagnostic operating characteristics, the diagnostic strategies assessed, and the 
methodologies used. despite this variation, these studies have consistently 
concluded that p e t has favourable cost-effectiveness characteristics as compared 
with non-p e t strategies.
The Impact of Positive Surgical Resection Margins and Short 
Disease-Free Interval on Survival Following Relapse After 
Esophagectomy and Adjuvant Chemoradiation Therapy in high-
Risk Esophageal Cancer
Yu E, Tai P, Malthaner R, Stitt L, Rodrigues G, Dar R, Yaremko B, 
Younus J, Sanatani M, Vincent M, Dingle B, Fortin D, Inculet R. Lon-
don Health Science Centre, University of Western Ontario, London, 
Ontario, and Allan Blair Cancer Center, Regina, Saskatchewan.
Objective:  This study investigated the effect of resection margin status and 
time interval to relapse on outcomes in high-risk esophageal cancer patients.
Patients and Methods:  during 1989–1999, we followed high-risk re-
sected esophageal cancer patients who completed postoperative chemoradiation 
therapy. adjuvant chemotherapy consisted of 4 cycles of epirubicin, cisplatin, and 
5-flurouracil (e c f ), with epirubicin omitted during the radiation therapy (r t ) phase. 
Total r t  dose was 45–60 Gy at 1.8–2.0 Gy per fraction. Patients who relapsed after 
a disease-free interval of more than 3 months were treated with palliative chemo-
radiation when appropriate. Patients who relapsed after a disease-free interval of 
3 months or less were treated with best supportive care. logistic regression and 
log-rank tests were used for post-recurrence survival analysis.
Results:  Of the 69 patients treated with adjuvant chemoradiation post-
esophagectomy, 46 patients experienced recurrence. Median time to relapse was 
28 months (range: 0.1–40 months). Median age of relapse patients was 61 years 
(range: 37–82 years). There were 42 male, 44 node-positive, 31 adenocarcinoma, 
and 33 clear resection margin post-esophagectomy patients. Median follow-up 
after recurrence was 30.5 months (range: 1.3–100 months). The median post-
recurrence overall survival duration was 5.8 months, with overall survival rates 
of 20%, 10%, and 5% at 12 months, 24 months, and 36 months respectively. Of 
the prognostic factors analyzed, only resection margin status and time interval 
to recurrence were statistically significant for patient outcome in univariate and 
multivariate analysis.
Conclusions:  Surgical resection margin status and time interval to disease 
relapse were independent prognostic factors for patient outcome.
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